acut
respiratori
distress
syndrom
ard
devast
clinic
manifest
pneumonia
mainli
base
immunedriven
patholog
mount
evid
suggest
fuel
maladapt
host
inflammatori
respons
involv
excess
activ
innat
immun
pathway
cytokin
storm
involv
cytokin
document
complement
activ
implic
initia
l
effector
mechan
exacerb
lung
injuri
preclin
model
sarscov
infectio
n
intervent
may
provid
broader
therapeut
control
complementmedi
share
first
coauthorship
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
inflammatori
damag
patient
herein
report
clinic
cours
patient
sever
ard
due
pneumonia
safe
success
treat
compstatinbas
complement
inhibitor
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
omero
dy
manag
director
amynda
pharmaceut
develop
complement
inhibitor
therapeut
purpos
author
declar
compet
interest
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
recent
declar
global
emerg
follow
outbreak
rais
awar
tackl
diseas
caus
effect
therapeut
mean
complement
consid
firstlin
defens
invad
pathogen
includ
viral
infect
recent
evid
strikingli
suggest
complem
nt
activ
promot
sever
acut
respiratori
syndrom
sar
coronaviru
pathogenesi
inde
block
activ
downstream
effector
gener
significa
ntli
attenu
lungdirect
proinflammatori
sequela
coronaviru
cov
infect
includ
ing
merscov
sarscov
limit
patholog
chang
impos
high
burden
covinfect
patient
genet
absenc
blockad
downstream
complem
nt
effector
shown
therapeut
promis
contain
detrimenta
l
proinflammatori
consequ
viral
spread
mainli
via
inhibit
monocyteneutrop
hil
activ
immun
cell
infiltr
lung
acut
respiratori
distress
syndrom
ard
mainli
base
immunedriven
patholog
observ
sever
case
deregul
activ
multipl
innat
immun
pathway
includ
complement
system
cytokin
circuitri
sever
procoagul
thrombogen
pathway
believ
fuel
hyperinflammatori
state
drive
ard
may
lead
multipl
organ
injuri
activ
posit
upstream
proinflammatori
innat
immun
circuit
contribut
thromboinflamm
organ
damag
therefor
intercept
could
promis
approach
broadli
inhibit
complement
activ
contain
system
complementmedi
inflammatori
reaction
may
fuel
tissu
destruct
inflamm
patient
new
gener
highli
select
potent
inhibitor
term
compstatin
clinic
develop
amynda
pharmaceut
variou
complementmedi
indic
smallsiz
peptid
inhibitor
primatehumanspecif
display
favour
pharmacologica
l
profil
greater
tissuepenetr
capac
larger
biolog
complement
inhibitor
previous
evalu
treatment
option
ard
therapeut
current
phase
ii
clinic
trial
shown
good
safeti
toler
human
volunt
phase
studi
light
recent
evid
link
activ
system
proinflammatori
respons
sarscov
infect
could
form
uniqu
base
develop
adjunct
antiinflammatori
therapi
counteract
emerg
outbreak
recent
clinic
develop
support
therapeut
merit
complement
inhibit
potenti
antiinflammatori
therapi
includ
report
five
case
j
u
r
n
l
p
r
e
p
r
f
patient
associ
pronounc
system
complement
activ
complementmedi
microvascular
injuri
coagulopathi
recent
preprint
report
complement
activatio
n
lung
biopsi
serum
patient
hospit
recent
outbreak
china
preliminari
analysi
remain
confirm
larger
studi
immedi
clinic
improv
result
blockad
two
patient
prompt
investig
rout
complement
therapeut
target
regard
clinic
trial
aim
evalu
safeti
efficaci
variou
complement
target
approach
patient
list
intern
registri
clinicaltrialsgov
given
intercept
compstatinbas
inhibitor
may
offer
broader
therapeut
coverag
agent
block
simultan
gener
downstream
proinflammatori
mediat
involv
ard
thrombot
microangiopathi
well
pois
clinic
evalu
antiinflammatori
agent
sever
case
infect
patient
caucasian
male
admit
hospit
critic
limb
ischemia
right
leg
requir
surgeri
meaning
past
medic
histori
due
histori
atrial
fibril
resolv
time
hospit
hypercholesterolemia
hypertens
associ
multipl
arteri
complic
mild
kidney
failur
inde
patient
coronari
arteri
diseas
requir
stent
recent
peripher
arteri
diseas
treat
embolectomi
fogarti
cathet
hospit
april
patient
diagnos
bilater
interstitia
l
pneumonia
see
chest
xray
figur
eventu
demonstr
caus
infect
sever
hypoxia
irrespect
oxygen
support
standard
ventimask
patient
start
noninvas
mechan
ventil
niv
continu
posit
airpressur
cpap
fraction
inspir
oxygen
given
hour
cycl
everi
hour
time
arteri
oxygen
pressur
blood
oxygen
satur
mmhg
respect
patient
increas
creactiv
protein
crp
mgl
increas
lactat
dehydrogenas
ldh
uil
leukocyto
gl
lymphocytopenia
patient
perform
statu
ps
use
eastern
cooper
oncolog
group
ecog
scale
consider
acut
respiratori
distress
syndrom
ard
due
patient
consid
candid
experiment
treatment
coronaviru
diseas
includ
complem
nt
april
th
compassion
use
discuss
patient
express
willing
includ
program
sign
irb
approv
inform
consent
patient
enrol
compassion
use
program
patient
treat
specif
antivir
therapi
wherea
antibacteri
prophylaxi
piperacillinetazobactam
ad
day
start
administr
continu
entir
treatment
period
april
th
day
treatment
start
baselin
patient
poor
gener
clinic
condit
sever
fatigu
sever
tachypnea
respiratori
act
per
minut
persist
dri
cough
pulmonari
auscultatio
n
reveal
midinspiratori
expiratori
coars
crackl
bilater
sever
ard
requir
cpap
cycl
hour
everi
hour
altern
oxygen
support
ventimask
lung
paramet
baselin
follow
mmhg
mmhg
ph
mmhg
blood
test
follow
white
blood
cell
wbc
x
l
absolut
neutrophil
count
anc
x
l
absolut
lymphocyt
count
alc
x
l
crp
mgl
ldh
uil
plasma
level
addit
lab
test
demonstr
mild
renal
function
impair
grade
transaminas
elev
glasgow
coma
scale
gc
quick
sequenti
organ
failur
assess
qsofa
score
respiratori
rate
respect
j
u
r
n
l
p
r
e
p
r
f
given
intraven
iv
peripher
vein
infus
dose
mgkg
mgkgday
given
initi
load
dose
administ
hour
side
effect
record
load
dose
immedi
complet
load
dose
mainten
dose
administ
continu
infus
treatment
period
infu
io
n
reaction
report
whole
durat
therapi
notabl
experimenta
l
treatment
worsen
renal
hepat
function
hour
initi
treatment
patient
show
dramat
improv
paramet
abnorm
baselin
result
quick
resolut
broad
inflammatori
respons
associ
particular
crp
ldh
progress
normal
leukocytosi
lymphocytopenia
improv
slowli
progress
figur
laboratori
find
associ
significa
nt
improv
respiratori
perform
gradual
decreas
oxygen
requir
figur
start
april
th
day
progress
wean
oxygen
supplement
allow
cpap
initi
reduc
altern
day
cycl
discontinu
april
th
day
ami
treatment
similarli
progress
continu
improv
blood
test
lung
function
also
continu
improv
inde
day
cpap
discontinu
patient
oxygen
requir
diminish
reduc
without
desatur
figur
interestingli
lung
function
improv
nt
associ
major
chang
imag
inde
bilater
interstiti
pneumonia
j
u
r
n
l
p
r
e
p
r
f
still
observ
chest
xray
perform
april
th
day
subsequ
ct
scan
perform
april
day
show
also
mild
right
pleural
effus
last
follow
april
rd
day
ventimask
patient
normal
respiratori
rate
normal
lung
auscult
absenc
respiratori
symptom
blood
test
follow
figur
wbc
x
l
anc
x
l
alc
x
l
crp
mgl
ldh
ul
gl
patient
mild
fatigu
ecog
perform
statu
improv
overal
demonstr
signific
clinic
improv
anticip
result
quick
resolut
covid
without
complic
notabl
concomit
critic
limb
ischemia
leg
worsen
abnorm
report
arteri
venou
ultrasound
imag
perform
april
th
clinic
laboratori
sign
cardiovascular
complic
occur
includ
thrombot
microangiopathi
compstatinbas
inhibito
r
safe
associ
favor
cours
patient
sever
pneumonia
system
hyper
inflamm
earli
clinic
result
indic
inhibit
hold
potenti
novel
antiinflammato
r
therapi
pave
way
systemat
prospect
trial
pharmaceutica
ls
develop
complement
inhibitor
therapeut
purpos
inventor
patent
patent
applic
describ
use
complement
inhibitor
therapeut
purpos
develop
amynda
jdl
also
inventor
compstatin
technolog
licens
apelli
pharmaceut
ie
pegyl
deriv
amr
receiv
research
support
alexion
novarti
alnylam
rapharma
lectur
fee
alexion
novarti
pfizer
apelli
serv
member
advisoryinvestig
board
alexion
achillion
apelli
biocryst
novarti
roch
samsung
sanofi
serv
consult
amynda
novarti
